Institutional & Family Asset Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Institutional & Family Asset Management’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	$1.03K	Hold	15	–	–	﹤0.01%	639
2024 Q1	$1.04K	Hold	15	–	–	﹤0.01%	634
2023 Q4	$1.07K	Hold	15	–	–	﹤0.01%	613
2023 Q3	$781	Buy	15 +6	+67%	+$350	﹤0.01%	635
2023 Q2	$570	Hold	9	–	–	﹤0.01%	671
2023 Q1	$487	Sell	9 -1	-10%	-$48	﹤0.01%	672
2022 Q4	$529	Hold	10	–	–	﹤0.01%	654
2022 Q3	$0	Hold	10	–	–	﹤0.01%	793
2022 Q2	$1K	Buy	+10	New	+$567	﹤0.01%	708

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Institutional & Family Asset Management's ITCI Position: Q2 2024 in Review

Institutional & Family Asset Management held its Intra-Cellular Therapies Inc. (ITCI) position steady in Q2 2024 at 15 shares worth $1.03K. The position accounts for ﹤0.01% of the portfolio, ranked #639.

Institutional & Family Asset Management first reported a position in ITCI in Q2 2022 and has held it in 9 quarters since. The position peaked at $1.07K in Q4 2023. 376 funds tracked by Wall St. Rank hold ITCI as of Q2 2024.

Institutional & Family Asset Management held 15 shares of Intra-Cellular Therapies Inc. worth $1.03K as of Q2 2024.
Institutional & Family Asset Management left its Intra-Cellular Therapies Inc. share count unchanged in Q2 2024.
Intra-Cellular Therapies Inc. made up ﹤0.01% of Institutional & Family Asset Management's portfolio in Q2 2024, its #639 holding.
Institutional & Family Asset Management first reported a position in Intra-Cellular Therapies Inc. in Q2 2022 and has held it in 9 quarters since.
Institutional & Family Asset Management's Intra-Cellular Therapies Inc. position peaked at $1.07K in Q4 2023.
376 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2024.

Based on Institutional & Family Asset Management's 13F filing for Q2 2024, filed 5 Jul 2024.